特发性肺动脉高压的表型分析:注册研究
基于COMPERA和ASPIRE两个欧洲肺动脉高压注册研究,分析符合IPAH诊断但伴低DLCO(<45%预计值)和吸烟史的患者。这类肺表型IPAH患者年龄较大、女性比例较低,对PAH治疗反应和生存均差于经典IPAH,而更接近第3组肺疾病相关肺动脉高压。
要点
- IPAH肺表型定义为DLCO<45%预计值且伴吸烟史,肺功能常正常或接近正常。
- 肺表型IPAH对PAH治疗反应差,生存率显著低于经典IPAH。
- 肺表型IPAH的临床特征与第3组肺动脉高压相似,而非经典IPAH。
核心结论
- 符合IPAH诊断且伴低DLCO和吸烟史的患者构成独特肺表型,其临床特征更接近肺疾病相关肺动脉高压而非经典IPAH。
- 该发现对发病机制、诊断和治疗均有启示,需进一步探索。
研究设计与样本
- 分析COMPERA(2007年启动)和ASPIRE(2001年起)两个欧洲肺动脉高压注册研究的数据。
- 比较经典IPAH、IPAH肺表型(DLCO<45%预计值且吸烟史)和第3组肺动脉高压患者的特征、治疗反应和生存。
- 样本量:经典IPAH 128例(COMPERA)和185例(ASPIRE);IPAH肺表型268例(COMPERA)和139例(ASPIRE);第3组肺动脉高压910例(COMPERA)和375例(ASPIRE)。
主要发现
- IPAH肺表型女性比例较低:COMPERA 35%(95例)、ASPIRE 54%(75例),经典IPAH为77%(99例)和72%(133例)。
关键数值与推荐
- IPAH肺表型定义:DLCO<45%预计值且伴吸烟史。
- 经典IPAH定义:无心肺合并症且DLCO≥45%预计值。
- 多数IPAH肺表型患者肺功能正常或接近正常,DLCO严重降低,胸部CT多数无或仅轻度肺实质受累。
临床怎么用
- 对符合IPAH诊断但伴低DLCO和吸烟史的患者,应认识到其表型独特,治疗反应和预后较差。
- 此类患者的管理可能更接近肺疾病相关肺动脉高压,而非经典IPAH。
局限性
- 研究为注册数据分析,可能存在选择偏倚和信息偏倚。
- 治疗反应数据仅来自COMPERA注册研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Among patients meeting diagnostic criteria for idiopathic pulmonary arterial hypertension (IPAH), there is an emerging lung phenotype characterised by a low diffusion capacity for carbon monoxide (DLCO) and a smoking history. The present study aimed at a detailed characterisation of these patients. METHODS: We analysed data from two European pulmonary hypertension registries, COMPERA (launched in 2007) and ASPIRE (from 2001 onwards), to identify patients diagnosed with IPAH and a lung phenotype defined by a DLCO of less than 45% predicted and a smoking history. We compared patient characteristics, response to therapy, and survival of these patients to patients with classical IPAH (defined by the absence of cardiopulmonary comorbidities and a DLCO of 45% or more predicted) and patients with pulmonary hypertension due to lung disease (group 3 pulmonary hypertension). FINDINGS: The analysis included 128 (COMPERA) and 185 (ASPIRE) patients with classical IPAH, 268 (COMPERA) and 139 (ASPIRE) patients with IPAH and a lung phenotype, and 910 (COMPERA) and 375 (ASPIRE) patients with pulmonary hypertension due to lung disease. Most patients with IPAH and a lung phenotype had normal or near normal spirometry, a severe reduction in DLCO, with the majority having no or a mild degree of parenchymal lung involvement on chest computed tomography. Patients with IPAH and a lung phenotype (median age, 72 years [IQR 65-78] in COMPERA and 71 years [65-76] in ASPIRE) and patients with group 3 pulmonary hypertension (median age 71 years [65-77] in COMPERA and 69 years [63-74] in ASPIRE) were older than those with classical IPAH (median age, 45 years [32-60] in COMPERA and 52 years [38-64] in ASPIRE; p<0·0001 for IPAH with a lung phenotype vs classical IPAH in both registries). While 99 (77%) patients in COMPERA and 133 (72%) patients in ASPIRE with classical IPAH were female, there was a lower proportion of female patients in the IPAH and a lung phenotype cohort (95 [35%] COMPERA; 75 [54%] ASPIRE), which was similar to group 3 pulmonary hypertension (336 [37%] COMPERA; 148 [39%] ASPIRE]). Response to pulmonary arterial hypertension therapies at first follow-up was available from COMPERA. Improvements in WHO functional class were observed in 54% of patients with classical IPAH, 26% of patients with IPAH with a lung phenotype, and 22% of patients with group 3 pulmonary hypertension (p<0·0001 for classical IPAH vs IPAH and a lung phenotype, and p=0·194 for IPAH and a lung phenotype vs group 3 pulmonary hypertension); median improvements in 6 min walking distance were 63 m, 25 m, and 23 m for these cohorts respectively (p=0·0015 for classical IPAH vs IPAH and a lung phenotype, and p=0·64 for IPAH and a lung phenotype vs group 3 pulmonary hypertension), and median reductions in N-terminal-pro-brain-natriuretic-peptide were 58%, 27%, and 16% respectively (p=0·0043 for classical IPAH vs IPAH and a lung phenotype, and p=0·14 for IPAH and a lung phenotype vs group 3 pulmonary hypertension). In both registries, survival of patients with IPAH and a lung phenotype (1 year, 89% in COMPERA and 79% in ASPIRE; 5 years, 31% in COMPERA and 21% in ASPIRE) and group 3 pulmonary hypertension (1 year, 78% in COMPERA and 64% in ASPIRE; 5 years, 26% in COMPERA and 18% in ASPIRE) was worse than survival of patients with classical IPAH (1 year, 95% in COMPERA and 98% in ASPIRE; 5 years, 84% in COMPERA and 80% in ASPIRE; p<0·0001 for IPAH with a lung phenotype vs classical IPAH in both registries). INTERPRETATION: A cohort of patients meeting diagnostic criteria for IPAH with a distinct, presumably smoking-related form of pulmonary hypertension accompanied by a low DLCO, resemble patients with pulmonary hypertension due to lung disease rather than classical IPAH. These observations have pathogenetic, diagnostic, and therapeutic implications, which require further exploration. FUNDING: COMPERA is funded by unrestricted grants from Acceleron, Bayer, GlaxoSmithKline, Janssen, and OMT. The ASPIRE Registry is supported by Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
引用
- Hoeper MM, Dwivedi K, Pausch C, et al. Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis. Lancet Respir Med. 2022. PMID: 35777416. doi:10.1016/S2213-2600(22)00097-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。